



touchREVIEWS in RMD

VOLUME 1 • ISSUE 2 • 2022

EDITOR-IN-CHIEF: PETER TAYLOR

Deucravacitinib: An Oral, Selective, Allosteric Tyrosine kinase 2 Inhibitor for Active Systemic Lupus Erythematosus

Ronald van Vollenhoven

Immunomodulation with Methotrexate Improves Treatment Response to Pegloticase in Uncontrolled Gout

Jeff Peterson

Is There a Place for Complement Inhibition with Monoclonal Anti-C5a Antibody Vilobelimab in the Treatment of Patients with ANCA-associated Vasculitis?

Gatr-Alnada Gheriani, Bharat Kumar and Petar S Lenert

Osteoarthritis: Advances and Emerging Treatments

Fiona Kirkham-Wilson and Elaine Dennison

www.touchIMMUNOLOGY.com


touchREVIEWS

in RMD

Volume 1 • Issue 2 • 2022

touchREVIEWS in RMD is an international, peer-reviewed, free-to-access journal developed for touchIMMUNOLOGY.com

Cover image: Joint treatment abstract background by reinegX © adobestock.com



touchIMMUNOLOGY.com wishes to thank the organisations below for their assistance. This does not constitute any official endorsement.



Editorial Directors

Gina Furnival
Helen Fowler
Katey Gabrysch
Sophie Nickelson

Commissioning Editors

Victoria Jones
Shanice Allen

Editorial Workflow

Lisa Glass
Heather Hall
Marianna Mignani
Atiya Henry
Danielle Crosby

Design Manager

Julie Stevenson

Group Head Medical & Editorial

Nicola Cartridge
E: nicola.cartridge@touchmedicalmedia.com
T: +44 (0)20 7193 3186

CEO & Managing Director

Barney Kent
E: barney.kent@touchmedicalmedia.com
T: +44 (0)20 7193 3009

Head of Strategic Partnerships

Caroline Markham
E: caroline.markham@touchmedicalmedia.com
T: +44 (0)20 7193 3704

All information obtained by Touch Medical Media and each of the contributors from various sources is as current and accurate as possible. However, due to human or mechanical errors, Touch Medical Media and the contributors cannot guarantee the accuracy, adequacy or completeness of any information, and cannot be held responsible for any errors or omissions, or for the results obtained from the use thereof. Where opinion is expressed, it is that of the authors and does not necessarily coincide with the editorial views of Touch Medical Media. Statistical and financial data in this publication have been compiled on the basis of factual information and do not constitute any investment advertisement or investment advice. For the avoidance of doubt, the information contained in this publication is intended for use by licensed medical professionals. The content should not be considered medical advice, diagnosis or treatment recommendations.

© 2022 Touch Medical Media Group Holdings Ltd is a private limited company registered in England and Wales at Lancashire Gate, 21 Tiviot Dale, Stockport, Cheshire, SK1 1TD, UK, with registered number 08197142. All rights reserved. eISSN 2635-1420



www.touchmedicalmedia.com

touchREVIEWS

in RMD

Editor-in-Chief

Peter Taylor
University of Oxford, Oxford, UK

touchIMMUNOLOGY Expert Faculty

Richard Furie
Division of Rheumatology, Northwell Health and Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA

David McLain
McLain Medical Associates, Birmingham, AL, USA

Arthur Kavanaugh
Center for Innovative Therapy, University of California, San Diego, CA, USA

Maria-Antonietta D'Agostino
Versailles-Saint-Quentin University and University Hospital Ambroise Paré, Boulogne-Billancourt, France

Elena Nikiforou
Centre for Rheumatic Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK

Jérôme Avouac
Université de Paris, Hôpital Cochin, Service de Rhumatologie, Paris, France

Petar Lenert
The University of Iowa, Iowa City, IA, USA

Nicholas Fuggle
MRC Lifecourse Epidemiology Centre, Southampton, UK

Raj Sengupta
The Royal National Hospital for Rheumatic Diseases, Bath, UK

Alessia Alunno
The University of L'Aquila, L'Aquila, Italy

Rebecca Fischer-Betz
Heinrich-Heine University, Düsseldorf, Germany

Lisa Alexandra Christ
Bern University Hospital, University of Bern, Switzerland

Su Lwin
Genetic Skin Disease Group, St John's Institute of Dermatology, King's College London, London, UK

Tiago Torres
Centro Hospitalar, Universitário do Porto, Porto, Portugal

Adam Reich
University of Rzeszow, Rzeszów, Poland

Sarosh Irani
Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK

Eva Monoz Couselo
Vall d'Hebron Hospital, Barcelona, Spain

Kevan Herold
Yale School of Medicine, New Haven, CT, USA

Gil Y Melmed
Center for Inflammatory Bowel Diseases, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Maria Oliva-Hemker
Johns Hopkins University School of Medicine, Baltimore, MD, USA

William Damsky
Yale School of Medicine, New Haven, CT, USA

Marcus Maurer
Charité – Universitätsmedizin Berlin, Berlin, Germany

Christopher Griffiths
Dermatology Centre, Barnes Building, Salford Royal NHS Foundation Trust, Manchester, UK

Emek Kocaturk
Koç University School of Medicine, Istanbul, Turkey

touchREVIEWS

in RMD

Established: January 2021 Frequency: Bi-annual
Current edition: Volume 1 Issue 2

Aims and Scope

- *touchREVIEWS in RMD* enables time-pressured physicians to stay abreast of major advances and opinion in international rheumatology practice.
- *touchREVIEWS in RMD* comprises balanced and comprehensive articles, addressing the most important and salient developments in the field of rheumatology.
- *touchREVIEWS in RMD* endeavours to support physicians, clinicians and related healthcare professionals in continuously developing their knowledge, effectiveness and productivity. The editorial policy has been designed to encourage discussion among this peer group.
- Comprehensive bibliographies for each article mean that *touchREVIEWS in RMD* is an informative and valuable reference tool for use throughout the year.
- All articles are subject to peer review, and must adhere to the ICMJE, GPP-3, and COPE guidelines.

Structure and Format

- *touchREVIEWS in RMD* is a peer-reviewed, free-to-access, bi-annual journal comprising expert interviews, review articles, editorials, and original research.
- The structure of each edition of the publication comprises section categories determined by the Managing Editor. The degree of coverage assigned to each category is the decision of the Managing Editor, and in part reflects the views of the Editorial Board.
- All articles disclose any author disclosures along with any funding, financial support, and medical writing assistance.
- Each edition of *touchREVIEWS in RMD* is published in full online at www.touchIMMUNOLOGY.com

Editorial Expertise

touchREVIEWS in RMD is supported by various levels of expertise:

- Guidance from an Editorial Board consisting of leading authorities from a variety of disciplines in immunology.
- Invited contributors who are recognised authorities from their respective fields.
- Peer review – conducted by experts appointed for their experience and knowledge of a specific topic.
- An experienced team of editors and technical editors.

Peer Review

- On submission, all articles are assessed by the Managing Editor to determine their suitability for inclusion and appropriateness for peer review.
- The Managing Editor identifies at least two appropriate reviewers, who are selected on the basis of their specialist knowledge in the relevant area, following consultation with a member of the Editorial Board where necessary.

- We aim to have the final peer review decision within 4 weeks.
- Following review, papers are either accepted without modification, returned to the author(s) to incorporate required changes or not accepted for publication.
- The Managing Editor reserves the right to accept or reject any proposed amendments on the advice of the Editorial Board and reviewers.

Submissions and Instructions for Authors

- The Managing Editor commissions articles with guidance from the Editorial Board and unsolicited articles are welcomed.
- The Managing Editor is always keen to hear from authors wishing to discuss potential submissions, and will give due consideration to any proposals. Please contact the Managing Editor for further details.
- The 'Instructions for Authors' information is available for download at www.touchIMMUNOLOGY.com

Distribution and Readership

touchREVIEWS in RMD is distributed bi-annually through controlled circulation to healthcare and pharmaceutical professionals in the field internationally.

Free-to-access

All articles are free-to-access, which allows everyone in the rheumatology field to download published articles for free.


Online

www.touchmedicalmedia.com provides clinicians and other industry professionals with a free resource of articles from over nine titles, spanning eight therapy areas including cardiology, endocrinology, immunology, neurology, oncology, ophthalmology, infectious diseases and respiratory.

Society Partners

touchIMMUNOLOGY.com has developed very valuable society partnerships with the most respected not-for-profit medical societies internationally. These partnerships are key as touchIMMUNOLOGY.com helps to promote awareness of these medical societies while also providing free-to-access, peer-reviewed articles and multimedia content to the society members, which ensures that the community is kept up-to-date with the latest cutting-edge content and opinion from world-renowned doctors.

About Touch Medical Media


Touch Medical Media publishes a rich and diverse portfolio of free-to-access, peer-reviewed journals across the clinical and pharmaceutical arenas. Touch Medical Media aims to assist in the education and practice of healthcare and pharmaceutical professionals. 



What's new for eosinophilic oesophagitis?

A case based discussion
of patient care

Watch Now



Understanding alopecia areata:

Current perspectives and emerging therapies for a complex disease

Learn more



Join the **touchIMMUNOLOGY** online community for **FREE** access to



Practical articles



Expert interviews



News and insights



 **touch™**
IMMUNOLOGY

Visit touchIMMUNOLOGY.com



Facebook



Twitter



Instagram




LinkedIn



YouTube



Podcast



Foreword

37 Foreword

Peter C Taylor – Editor-in-Chief
University of Oxford, Oxford, UK

Expert Interviews

COVID-19

38 SARS-CoV-2 Vaccine Immunogenicity in Patients with Autoimmune Inflammatory Rheumatic Diseases

An Expert Interview with Victoria Furer
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Systemic Lupus Erythematosus

40 Deucravacitinib: An Oral, Selective, Allosteric Tyrosine kinase 2 Inhibitor for Active Systemic Lupus Erythematosus

An Expert Interview with Ronald van Vollenhoven
Amsterdam University Medical Centers, Amsterdam, the Netherlands

Editorials

Gout

42 Immunomodulation with Methotrexate Improves Treatment Response to Pegloticase in Uncontrolled Gout

Jeff Peterson
Western Washington Arthritis Clinic, Bothell, WA, USA

Rheumatic Diseases


44 Can I Prevent Developing a Rheumatic and Musculoskeletal Disease Through Lifestyle Changes? A Focus on Nutrition

Elena Philippou^{1,2} and Elena Nikiphorou^{3,4}
1. Department of Life and Health Sciences, School of Sciences and Engineering, University of Nicosia, Nicosia, Cyprus; 2. Department of Nutritional Sciences, King's College London, London, UK; 3. Department of Rheumatology, King's College Hospital, London, UK; 4. Centre for Rheumatic Diseases, King's College London, London, UK

Vasculitis

46 Is There a Place for Complement Inhibition with Monoclonal Anti-C5a Antibody Vilobelimab in the Treatment of Patients with ANCA-associated Vasculitis?

Gatr-Alnada Gheriani, Bharat Kumar and Petar S Lenert
Division of Immunology, Carver College of Medicine, The University of Iowa, Iowa City, IA, USA



Reviews

Axial Spondyloarthritis

50 **The Complement System in Spondyloarthritis: What Do We Know?**

Clara Elbæk Mistegaard^{1,2,3} and Fabian Proft^{4,5}

1. Department of Biomedicine, Aarhus University, Aarhus, Denmark; 2. Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; 3. Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; 4. Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, Berlin, Germany; 5. Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

Osteoarthritis

57 **Osteoarthritis: Advances and Emerging Treatments**

Fiona Kirkham-Wilson¹ and Elaine Dennison²

1. Royal Hampshire County Hospital, Winchester, UK; 2. MRC Lifecourse Epidemiology Centre, Southampton, UK

Systemic Sclerosis

61 **Advances in the Treatment of Systemic Sclerosis**

Ariane L Herrick^{1,2}

1. Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK; 2. NIHR Manchester Biomedical Research Centre, Manchester, UK